General Information of Drug (ID: DM5VF04)

Drug Name
GD2-CART01 Drug Info
Indication
Disease Entry ICD 11 Status REF
Neuroblastoma 2D11.2 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM5VF04

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Ganglioside GD2 (GD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [2]
Anti-GD2 CART DMVQHBK Neuroblastoma 2D11.2 Phase 2 [3]
Hu3F8 mAb DM9MKQ5 Neuroblastoma 2D11.2 Phase 2 [4]
APN301 DMGNFBC Neuroblastoma 2D11.2 Phase 2 [5]
4SCAR-GD2 DMEGSU5 Tumour 2A00-2F9Z Phase 1/2 [6]
CAR-T cells targeting CD2 DMJVENR Cervical cancer 2C77.0 Phase 1/2 [7]
CAR-T cells targeting GD2 DMFCPG0 Glioma 2A00.0 Phase 1/2 [8]
CAR-T cells targeting GD2 DMFCPG0 Glioma 2A00.0 Phase 1/2 [9]
IC9-GD2-CD28-OX40 DMRYHWA Neuroblastoma 2D11.2 Phase 1 [10]
Anti-GD2 T-cells (1RG-CART) DMBVUFL Neuroblastoma 2D11.2 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ganglioside GD2 (GD2) TT80ARU NOUNIPROTAC CAR-T-Cell-Therapy [1]

References

1 ClinicalTrials.gov (NCT03373097) Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma
2 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
3 ClinicalTrials.gov (NCT02765243) Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of Apeiron Biologics.
6 ClinicalTrials.gov (NCT02992210) Study on GD2 Positive Solid Tumors by 4SCAR-GD2
7 ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer
8 ClinicalTrials.gov (NCT03252171) CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
9 ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
10 ClinicalTrials.gov (NCT01822652) 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
11 ClinicalTrials.gov (NCT02761915) A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)